FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386447675> ?p ?o ?g. }

• W4386447675 abstract "Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity in endometrial cancer (EC). The primary end point was to assess progression-free survival (PFS) with once-weekly oral selinexor in patients with advanced or recurrent EC.ENGOT-EN5/GOG-3055/SIENDO was a randomized, prospective, multicenter, double-blind, placebo-controlled, phase III study at 107 sites in 10 countries. Patients 18 years or older with histologically confirmed EC were enrolled. All had completed a single line of at least 12 weeks of taxane-platinum combination chemotherapy and achieved partial or complete response. Patients were assigned to receive 80 mg oral selinexor once weekly or placebo with 2:1 random assignment (ClinicalTrials.gov identifier: NCT03555422).Between January 2018 and December 2021, 263 patients were randomly assigned, with 174 allocated to selinexor and 89 to placebo. The median PFS was 5.7 months (95% CI, 3.81 to 9.20) with selinexor versus 3.8 months (95% CI, 3.68 to 7.39) with placebo (hazard ratio [HR], 0.76 [95% CI, 0.54 to 1.08]; two-sided P = .126), which did not meet the criteria for statistical significance in the intent-to-treat population. Incorrect chemotherapy response stratification data for 7 (2.7%) patients were identified. In a prespecified exploratory analysis of PFS in audited stratification data, PFS for selinexor met the threshold for statistical significance (HR, 0.71; 95% CI, 0.499 to 0.996; two-sided P = .049). Furthermore, patients with the TP53 wild-type (wt) EC had a median PFS of 13.7 and 3.7 months with selinexor and placebo. The most common grade 3 treatment-related adverse events were nausea (9%), neutropenia (9%), and thrombocytopenia (7%).The significance level for PFS was only met in the audited analysis. However, a preliminary analysis of a prespecified exploratory subgroup of patients with TP53wt EC showed promising results with selinexor maintenance therapy." @default.
• W4386447675 created "2023-09-06" @default.
• W4386447675 creator A5000058797 @default.
• W4386447675 creator A5000568505 @default.
• W4386447675 creator A5002158178 @default.
• W4386447675 creator A5002295761 @default.
• W4386447675 creator A5002528957 @default.
• W4386447675 creator A5002555374 @default.
• W4386447675 creator A5002574698 @default.
• W4386447675 creator A5003060935 @default.
• W4386447675 creator A5003297500 @default.
• W4386447675 creator A5003573307 @default.
• W4386447675 creator A5003661852 @default.
• W4386447675 creator A5003944586 @default.
• W4386447675 creator A5004586568 @default.
• W4386447675 creator A5005902146 @default.
• W4386447675 creator A5006031339 @default.
• W4386447675 creator A5007605375 @default.
• W4386447675 creator A5008066397 @default.
• W4386447675 creator A5008353011 @default.
• W4386447675 creator A5008582313 @default.
• W4386447675 creator A5008683883 @default.
• W4386447675 creator A5008765868 @default.
• W4386447675 creator A5009523282 @default.
• W4386447675 creator A5009967316 @default.
• W4386447675 creator A5011045410 @default.
• W4386447675 creator A5012278873 @default.
• W4386447675 creator A5012330169 @default.
• W4386447675 creator A5014145810 @default.
• W4386447675 creator A5014611244 @default.
• W4386447675 creator A5015187893 @default.
• W4386447675 creator A5015735346 @default.
• W4386447675 creator A5015984427 @default.
• W4386447675 creator A5017985775 @default.
• W4386447675 creator A5018131884 @default.
• W4386447675 creator A5018884124 @default.
• W4386447675 creator A5020710893 @default.
• W4386447675 creator A5022029062 @default.
• W4386447675 creator A5023230423 @default.
• W4386447675 creator A5023508402 @default.
• W4386447675 creator A5023727769 @default.
• W4386447675 creator A5024010303 @default.
• W4386447675 creator A5026048739 @default.
• W4386447675 creator A5026806233 @default.
• W4386447675 creator A5027982720 @default.
• W4386447675 creator A5029514160 @default.
• W4386447675 creator A5030595144 @default.
• W4386447675 creator A5030595220 @default.
• W4386447675 creator A5031064268 @default.
• W4386447675 creator A5031268602 @default.
• W4386447675 creator A5031844208 @default.
• W4386447675 creator A5033192500 @default.
• W4386447675 creator A5033251451 @default.
• W4386447675 creator A5034016202 @default.
• W4386447675 creator A5035475871 @default.
• W4386447675 creator A5037590677 @default.
• W4386447675 creator A5037677450 @default.
• W4386447675 creator A5038232577 @default.
• W4386447675 creator A5038751879 @default.
• W4386447675 creator A5038966671 @default.
• W4386447675 creator A5039010220 @default.
• W4386447675 creator A5039578268 @default.
• W4386447675 creator A5040185143 @default.
• W4386447675 creator A5040331693 @default.
• W4386447675 creator A5041513544 @default.
• W4386447675 creator A5041575636 @default.
• W4386447675 creator A5042137756 @default.
• W4386447675 creator A5043064148 @default.
• W4386447675 creator A5046758725 @default.
• W4386447675 creator A5047066500 @default.
• W4386447675 creator A5048570626 @default.
• W4386447675 creator A5049011165 @default.
• W4386447675 creator A5050467390 @default.
• W4386447675 creator A5051352882 @default.
• W4386447675 creator A5054383411 @default.
• W4386447675 creator A5054988389 @default.
• W4386447675 creator A5055175375 @default.
• W4386447675 creator A5057755017 @default.
• W4386447675 creator A5058535647 @default.
• W4386447675 creator A5059735460 @default.
• W4386447675 creator A5060103872 @default.
• W4386447675 creator A5060430143 @default.
• W4386447675 creator A5060469228 @default.
• W4386447675 creator A5060699967 @default.
• W4386447675 creator A5060787566 @default.
• W4386447675 creator A5061185668 @default.
• W4386447675 creator A5061371368 @default.
• W4386447675 creator A5062635658 @default.
• W4386447675 creator A5063696834 @default.
• W4386447675 creator A5064599843 @default.
• W4386447675 creator A5064636994 @default.
• W4386447675 creator A5065058975 @default.
• W4386447675 creator A5066909949 @default.
• W4386447675 creator A5069269249 @default.
• W4386447675 creator A5070219310 @default.
• W4386447675 creator A5071060598 @default.
• W4386447675 creator A5071420169 @default.
• W4386447675 creator A5071527937 @default.
• W4386447675 creator A5071651097 @default.
• W4386447675 creator A5072204852 @default.

• next